Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (RELAX)

AbbVie

Status: Completed

Conditions: Severe Crohn's Disease; Anxiety

Study type: Observational

Funder types: Industry

Identifiers

NCT01428115

P12-705

Details and patient eligibility

About

It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.

Such findings have to be taken into consideration when making an educated guess that psychological factors such as depression and anxiety in particular interact with the course of Crohns disease. Therefore the treatment of the underlying disease may have a significant influence on the level of psychological disorders.

Several studies have shown that treatment with tumor necrosis factor alpha (TNF-α) antibodies ameliorates the emotional/psychological status of patients, however the impact of adalimumab therapy on anxiety correlated with the status of inflammatory bowel disease (IBD) remains unclear.

The primary objective of this study was to describe and evaluate changes in levels of anxiety assessed by validated patient questionnaires after 6 months of treatment with adalimumab.

Enrollment: 83 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients for whom Adalimumab (Humira) therapy is indicated and has been prescribed according to the product label and who meet the following criteria:

  • Male and female patients aged 18 to 65 years suffering from severe active Crohns Disease, attending a routine medical visit.
  • Able to complete questionnaires.
  • Patients with status active severe Crohns disease which required immunosuppressive treatment
  • Patients must fulfil international and national guidelines for the use of a biologic therapies in Crohns Disease (Chest X-ray and interferon gamma release assay (IGRA) or PPD (purified protein derivative)-skin test negative for tuberculosis).
  • Patients have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
  • Patients who have been prescribed in line with the European Summary of Product Characteristics (SMPC)

Exclusion criteria

• The following patients will not be included in this observational study:

  • Previous therapy with TNF-α blocker within the last 8 weeks
  • Active Central Nervous System opportunistic infections or Central Nervous System malignancies.
  • History of Cerebrovascular Accident
  • Abuse of illicit substances (such as psychoactive drugs) within the previous 3 months
  • Change of medication-based treatment of generalized anxiety and panic disorder, psychiatric disorder
  • No informed consent
  • Contraindication to adalimumab (Humira) therapy according to the SMPC
  • Current or planned pregnancy
  • Lactation according to SMPC
  • Planned change of site within the next 24 weeks.

Trial design

83 participants in 1 patient group

Patients with severe active Crohn's disease

Description:

Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.